2023 CONFERENCE REGISTRATION
The Cancer Molecular Therapeutics Research Association Board of Directors is pleased to announce the location for the 2023 Molecular Therapeutics of Cancer Conference is at the
Watkins Glen Harbor Hotel in Watkins Glen, New York.
Save your dates for July 23 - 27, 2023.
We would love to see you there!
The CMTRA board will select short talks to be presented on Wednesday afternoon from the presented posters.
Abstract Submission: If you would like to present a poster, please submit and abstract here.
After registration, please contact the Watkins Glen Harbor Hotel directly to reserve your room with our special conference rate. There are limited rooms at the hotel, please reserve yours early.
Hotel Reservation: Please contact the Watkins Glen Harbor Hotel at their reservation number (607) 535-6116. Make sure to mention that you are with The Cancer Molecular Therapeutics Research Association Group to receive the conference rate.
Student housing: There is limited student housing available at a discounted rate. Please contact Tatum Street at email@example.com to take advantage of this.
Transportation: Please continue to go ahead and book your flight and transportation after registration for the CMTRA conference. Transportation from the two surrounding airports, Rochester International Airport or Hancock International Airport in Syracuse, are both an hour and a half drive from the Harbor Hotel. The easiest way to arrive at The Harbor Hotel will be by rental car.
Individual Uber and Lyft transportation is also available if you are arriving or leaving on alternative dates or prefer to manage your transportation independently. Please keep in mind, Uber and Lyft are not available in the Watkins Glen area so transportation companies will need to be arranged for departure dates.
Guest Pricing: Guest meal plans will be offered for the duration of the conference at registration. Payment for guest meal plans will be accepted by check. The guest meal plan amount will be announced 1 month in advance of the conference. If you plan to have a guest, please contact Tatum Street at street@reliantglycosciences.
ABOUT THE CANCER MOLECULAR THERAPEUTICS RESEARCH ASSOCIATION
The Full Story
Provides a dynamic platform for the most contemporary and controversial approaches to the treatment of cancer
Dedicates half of the formal presentation time to questions and answers to promote rigorous discussion
Welcomes an active dialog among investigators from industry, academia, government and, foundations
Enables informal and intimate (150 participants) networking for graduate students, postdoctoral fellows, residents and, early-stage and established investigators
Awards the top four poster presenters with the opportunity to orally present their research and attend next year’s conference free of charge
Builds on the legacy of more than two decades of annual conference
The 2022 CMTRA Conference was held in the Skamania Lodge in Stevenson, WA. We had an incredible time in July from 17- 21, 2022!
Congratulations to the following winners of the 2022 poster session:
See below photos from the event and the conference program.
The Cancer Molecular Therapeutics Research Association [CMTRA] was created in 2008 to organize and host the annual Molecular Therapeutics of Cancer meeting. The meeting objective is to provide a forum for presentation and discussion of contemporary research in the field of cancer drug development and therapy. Modeled after small Gordon-type conferences, the meeting provides an opportunity for young and established researchers to discuss and challenge current paradigms for cancer drug development and therapy, as well as a venue where novel ideas can be presented with anticipation of lively debate.
Officers & Board Members
MARTIN MCMAHON, PH.D.
Cumming-Presidential Professor of Cancer Biology & Senior Director for Preclinical Translation |
Huntsman Cancer Institute & Dept. of Dermatology | University of Utah | Salt Lake City, UT
LORI FRIEDMAN, PH.D.
Chief Scientific Officer | ORIC Pharmaceuticals | South San Francisco, CA
JAMES D. WINKLER, PH.D.
Chief Scientific Officer | OnKure Therapeutics
WILLIAM J. PLACZEK, PH.D.
Associate Professor | Department of Biochemistry and Molecular Genetics; Director | Central Alabama High-Field NMR Facility; Co-Director | Structural Biology Shared Facility, Cancer Center | The University of Alabama at Birmingham
PETER HOUGHTON, PH.D.
Director | Greehey Children's Cancer Research Institute | UT Health at San Antonio, San Antonio, TX
ROBERT KRAMER, PH.D.
RAKramer Consulting LLC | Newton, PA
MARY-ANN BJORNSTI, PH.D.
Professor & Chair Newman H Waters Chair of Clinical Pharmacology | Department of Pharmacology & Toxicology | University of Alabama at Birmingham
PHILLIP A. DENNIS, M.D., PH.D.
Vice President Lung Cancer | Sanofi Oncology
SHIVA MALEK, PH.D.
Global Head, Oncology | Novartis Institute of Biomedical Research
ZAHID H. SIDDIK, PH.D.
Professor of Medicine | Pharmacology Department of Experimental Therapeutics | MD Anderson Cancer Center | Houston, TX
ELI M. WALLACE, PH.D.
Chief Scientific Officer, Oncology | BridgeBio | Dallas, TX
BOB ABRAHAM, PH.D.
Executive Vice President | Head of Cancer Biology | Odyssey Therapeutics
Emeritus Board Members:
Alan Eastman, Ph.D. - Professor Emeritus | Norris Cotton Cancer Center | Dartmouth College | Hanover, NH
John A. Hickman, D.Sc. - Agon Consulting, Paris
Branimir I. Sikic, M.D. - Director | Stanford Clinical & Translational Research Unit; Co-director | Stanford University School of Medicine | Stanford, CA